HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Xamoterol (Corwin)

A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.

Also Known As:

Corwin; Carwin; ICI-118587; Xamoterol Fumarate; Xamoterol Hemifumarate; Xamoterol Maleate (2:1); Xamoterol Monohydrobromide; Xamoterol Monohydrochloride; Xamoterol, (S)-Isomer; Xamtol; Fumarate, Xamoterol; Hemifumarate, Xamoterol; ICI 118587; ICI118587; Monohydrobromide, Xamoterol; Monohydrochloride, Xamoterol; 4-Morpholinecarboxamide, N-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-, (+-)-

Networked: 158 relevant articles (19 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hashemi-Hezaveh, Seyed-Milad: 1 article (01/2014)
2.	Sheidadoust, Hadi: 1 article (01/2014)
3.	Zarrindast, Mohammad-Reza: 1 article (01/2014)
4.	Torkaman-Boutorabi, Anahita: 1 article (01/2014)
5.	East, Michelle: 1 article (06/2012)
6.	Priestley, Matthew: 1 article (08/2011)
7.	Belichenko, Pavel: 1 article (08/2011)
8.	Saw, Nay: 1 article (08/2011)
9.	Shamloo, Mehrdad: 1 article (08/2011)
10.	Tun, Christine: 1 article (08/2011)

Related Diseases

1.	Heart Failure 02/01/1990 - "The beneficial effects of xamoterol on both systolic and diastolic function suggested that it would be effective in patients with mild-to-moderate heart failure, and this was demonstrated in small placebo-controlled studies where effort tolerance and symptoms were improved. " 01/01/1985 - "Thus, the beneficial effects of Xamoterol were maintained after prolonged therapy particularly in patients with class II-III heart failure; patients in class IV benefited less from this therapy. " 03/25/1993 - "This improvement in exercise capacity and overall quality of life in patients treated with xamoterol has been confirmed in further controlled trials of patients with mild-to-moderate heart failure (NYHA class I and II). " 11/01/1989 - "We conclude that xamoterol produces sustained improvement in symptoms and exercise duration in mild to moderate heart failure." 03/01/1990 - "Acute and chronic administration of xamoterol, a new beta 1 partial agonist, to patients with congestive heart failure has been shown to improve myocardial contractility, as indicated by increases in the peak rate of rise in left ventricular pressure, left ventricular ejection fraction, and cardiac output. "
2.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 03/25/1993 - "Long-term studies of xamoterol in patients with idiopathic dilated cardiomyopathy have shown improved cardiac performance and exercise tolerance, while exercise heart rate, left ventricular ejection fraction, and pulmonary artery wedge pressure were decreased. " 01/01/1992 - "Risk factors and the effects of xamoterol in idiopathic dilated cardiomyopathy." 01/01/1992 - "Effects of long-term xamoterol in idiopathic dilated cardiomyopathy." 04/01/1991 - "Thus, in idiopathic dilated cardiomyopathy, xamoterol exhibited only minor hemodynamic effects whereas myocardial contraction economy and efficiency were significantly reduced." 04/01/1991 - "The effect of the partial beta-1-adrenoceptor agonist xamoterol on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy."
3.	Orthostatic Hypotension (Postural Hypotension) 04/01/1990 - "Xamoterol may therefore be useful in the treatment of postural hypotension." 02/01/1992 - "Our observations suggest that 1) beta 1-selective, high intrinsic sympathomimetic activity of xamoterol increases blood pressure and heart rate in patients with SDS as a consequence of their prevailing beta 1-adrenoceptor hypersensitive state, and 2) blood pressure monitoring over 24 hours appears to have important advantages in evaluating the therapeutic effects on postural hypotension." 02/01/1992 - "Xamoterol, a cardioselective beta 1-adrenoceptor partial agonist, has been reported to be effective on postural hypotension. " 02/01/1990 - "Xamoterol lessened the total number of symptomatic episodes of orthostatic hypotension by 67 per cent. " 01/01/1986 - "Xamoterol seems to be a useful alternative in the treatment of postural hypotension."
4.	Stroke (Strokes) 05/06/1991 - "Cardiac index, stroke volume and stroke work index at rest were significantly improved after i.v. administration of xamoterol and consistent with net agonist effects. " 01/01/1989 - "3. On exercise, xamoterol produced a considerable reduction in heart rate increase, improved stroke volume and left ventricular stroke index and lowered double product. " 03/01/1989 - "Xamoterol produced significant improvements in resting cardiac index (2.51 +/- 0.15 to 2.80 +/- 0.14 l min-1 m-2; P less than 0.001), stroke volume (62 +/- 4 to 75 +/- 5 mljbeat-1; P less than 0.001) and stroke work index (42.4 +/- 3.6 to 47.7 +/- 3.9 gm beat-1 m-2; P less than 0.01). " 04/01/1986 - "Repeated doses of Corwin produced no significant change in left ventricular performance, while a trend towards decreased blood pressure and stroke work was seen. " 03/01/1991 - "At 4 h post-dose the mean differences were: xamoterol-enalapril 13/10 mm Hg (P = 0.01 systolic, 0.0007 diastolic) and placebo-enalapril 23/9 mm Hg. 3. Stroke and minute distances were marginally less 4 h following xamoterol than following enalapril: mean (s.e. "
5.	Atrial Fibrillation 10/01/1984 - "Thus Corwin appears to be effective in stabilising heart rate during atrial fibrillation both at rest and during exercise in digitalised patients." 10/01/1984 - "The effect of Corwin, a new oral beta, partial agonist, on the ventricular response to atrial fibrillation was studied in digitalised patients during 24 hour ambulatory electrocardiography and during exercise on a treadmill in a double blind placebo controlled crossover trial. " 07/01/1995 - "Xamoterol improves the control of chronic atrial fibrillation in elderly patients." 10/01/1990 - "Xamoterol reduced both the circadian variation in ventricular response to atrial fibrillation and exercise tachycardia by modulating the heart rate according to the prevailing level of sympathetic activity. " 10/01/1992 - "In a placebo-controlled study the effects on ventricular rate regulation and exercise performance of xamoterol, 100 mg two times a day and 200 mg two times a day, and slow-release verapamil, 240 mg once a day, were assessed in 21 patients with chronic atrial fibrillation. "

Related Drugs and Biologics

1.	Digoxin (Digitek)
2.	carvedilol (Coreg)
3.	bucindolol
4.	Oxygen
5.	Xamoterol (Corwin)
6.	Metoprolol (Lopressor)
7.	Verapamil (Calan)
8.	Pindolol (LB 46)
9.	Atenolol (Tenormin)
10.	Diuretics

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Oral Administration
3.	Intravenous Infusions
4.	Intravenous Injections